Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 healthy volunteer study of ALRN-6924
NL-OMON52916Phase 1Active, not recruiting
- Sponsor
- Rein Therapeutics
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of sulanemadlin (2 arms), sponsored by Rein Therapeutics. Primary endpoint: Optimal cell cycle arrest in bone marrow. Started Nov 2020; status: active, not recruiting.
02
Drugs
sulanemadlin
Beyond the preview
Go deeper on NL-OMON52916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52916.